News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
315,601 Results
Type
Article (26080)
Company Profile (148)
Press Release (289373)
Section
Business (91242)
Career Advice (1289)
Deals (14141)
Drug Delivery (73)
Drug Development (38209)
Employer Resources (152)
FDA (7958)
Job Trends (8519)
News (153186)
Policy (13435)
Tag
Academia (1956)
Alliances (24975)
Alzheimer's disease (750)
Approvals (7902)
Artificial intelligence (83)
Bankruptcy (92)
Best Places to Work (7190)
Biotechnology (92)
Breast cancer (64)
Cancer (488)
Career advice (1135)
Cell therapy (124)
Clinical research (30037)
Collaboration (226)
Compensation (65)
COVID-19 (1287)
C-suite (52)
Cystic fibrosis (64)
Data (543)
Diabetes (78)
Diagnostics (3208)
Earnings (25271)
Employer resources (133)
Events (47306)
Executive appointments (176)
FDA (8239)
Funding (182)
Gene therapy (104)
GLP-1 (342)
Government (2253)
Healthcare (9769)
Infectious disease (1331)
Inflammatory bowel disease (80)
Interviews (192)
IPO (6284)
Job creations (1562)
Job search strategy (1000)
Layoffs (167)
Legal (2157)
Lung cancer (83)
Management (51)
Manufacturing (95)
Medical device (6171)
Medtech (6175)
Mergers & acquisitions (7948)
Metabolic disorders (214)
Neuroscience (917)
NextGen Class of 2024 (3652)
Non-profit (3443)
Northern California (693)
Obesity (130)
Opinion (113)
People (32765)
Phase I (8625)
Phase II (12956)
Phase III (11164)
Pipeline (119)
Postmarket research (1234)
Preclinical (3796)
Press Release (61)
Radiopharmaceuticals (115)
Rare diseases (131)
Real estate (3182)
Recruiting (58)
Regulatory (9672)
Research institute (1718)
Resumes & cover letters (165)
Southern California (571)
Startups (2360)
United States (6338)
Vaccines (248)
Weight loss (98)
Date
Today (81)
Last 7 days (432)
Last 30 days (1571)
Last 365 days (20332)
2024 (17262)
2023 (22459)
2022 (27552)
2021 (30632)
2020 (28328)
2019 (25200)
2018 (18733)
2017 (16364)
2016 (15825)
2015 (17415)
2014 (12650)
2013 (10239)
2012 (10756)
2011 (11091)
2010 (10054)
Location
Africa (473)
Arizona (74)
Asia (18236)
Australia (3310)
California (1498)
Canada (550)
China (105)
Colorado (59)
Connecticut (75)
Europe (45092)
Florida (224)
Georgia (67)
Illinois (166)
Indiana (147)
Maryland (242)
Massachusetts (1215)
Michigan (79)
Minnesota (131)
New Jersey (516)
New York (496)
North Carolina (419)
Northern California (693)
Ohio (80)
Pennsylvania (350)
South America (625)
Southern California (571)
Texas (187)
Washington State (123)
315,601 Results for "realta life sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).
March 28, 2024
·
3 min read
Drug Development
ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
ReAlta Life Sciences, Inc. today announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide platform, for the treatment of acute exacerbations of chronic obstructive pulmonary disease.
February 21, 2024
·
3 min read
Business
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
ReAlta Life Sciences, Inc. today announced the appointment of two experienced R&D leaders, John Baldoni, PhD and Eric Van Gieson, PhD to its Board of Directors, effective immediately.
January 24, 2024
·
5 min read
Press Releases
ReAlta Life Sciences Announces First Patient Dosed in Phase 2 Study Evaluating RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-versus-Host Disease
September 23, 2024
·
4 min read
Business
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
January 3, 2024
·
5 min read
Business
Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation
ReAlta Life Sciences was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
October 12, 2023
·
3 min read
BioCapital
ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress
ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
September 5, 2023
·
2 min read
Drug Development
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
ReAlta Life Sciences, Inc. today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).
October 24, 2023
·
3 min read
Drug Development
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of RLS-0071 in hospitalized patients with steroid-refractory acute graft-versus-host disease (aGvHD).
September 6, 2023
·
3 min read
Drug Development
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns
ReAlta Life Sciences today announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns.
August 1, 2023
·
3 min read
1 of 31,561
Next